Lyell Immunopharma (NASDAQ:LYEL) Major Shareholder Arch Venture Partners Ix, Llc Acquires 2,321,262 Shares of Company Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) major shareholder Arch Venture Partners Ix, Llc acquired 2,321,262 shares of the firm’s stock in a transaction dated Wednesday, November 4th. The shares were bought at an average cost of $10.77 per share, with a total value of $24,999,991.74. Following the completion of the acquisition, the insider directly owned 3,747,790 shares of the company’s stock, valued at $40,363,698.30. The trade was a 162.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Lyell Immunopharma Stock Down 2.8%

Shares of Lyell Immunopharma stock opened at $15.00 on Friday. Lyell Immunopharma, Inc. has a twelve month low of $7.20 and a twelve month high of $45.00. The company’s 50 day moving average is $10.85 and its 200 day moving average is $16.69. The company has a market cap of $367.56 million, a price-to-earnings ratio of -1.19 and a beta of -0.04.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Wednesday, November 4th. The company reported ($1.86) EPS for the quarter, topping analysts’ consensus estimates of ($2.06) by $0.20. The business had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.00 million. Lyell Immunopharma had a negative net margin of 1,701,066.75% and a negative return on equity of 101.30%. Sell-side analysts expect that Lyell Immunopharma, Inc. will post -7.16 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on LYEL shares. HC Wainwright reissued a “buy” rating on shares of Lyell Immunopharma in a report on Friday, September 11th. Royal Bank Of Canada set a $34.00 price target on Lyell Immunopharma in a research note on Friday, August 14th. Wall Street Zen raised shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Sunday, October 25th. Citigroup reiterated a “market outperform” rating on shares of Lyell Immunopharma in a research note on Friday, August 14th. Finally, Stifel Nicolaus started coverage on shares of Lyell Immunopharma in a research note on Thursday, August 6th. They issued a “buy” rating and a $36.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Lyell Immunopharma presently has an average rating of “Moderate Buy” and a consensus target price of $40.86.

Trending Headlines about Lyell Immunopharma

Here are the key news stories impacting Lyell Immunopharma this week:

• Positive Sentiment: Promising ronde-cel results: In data expected at the ASH 2026 meeting, ronde-cel produced a 91% overall response rate and 77% complete response rate among 44 patients with heavily pretreated large B-cell lymphoma; results in a 37-patient second-line cohort were 95% and 76%, respectively. Severe cytokine release syndrome was not observed in either cohort. These findings may strengthen the case for the treatment and its planned regulatory path. Ronde-cel clinical data
• Positive Sentiment: Funding and major-investor support: Lyell agreed to raise about $80 million from institutional investors, including ARCH Venture Partners, to advance ronde-cel toward a planned biologics license application. ARCH-related entities also disclosed purchases totaling about $25 million at $10.77 per share, a notable signal of investor backing. Private placement announcement SEC insider transaction filing
• Positive Sentiment: Analyst endorsement and earnings beat: Needham & Company assigned LYEL a “Buy” rating. Separately, quarterly loss per share of $1.86 was narrower than the $2.06 consensus estimate, though the company reported no revenue. Needham Buy rating Quarterly results
• Negative Sentiment: Share dilution and ongoing losses: The private placement involves issuing additional common shares, which dilutes existing holders. Lyell remains a clinical-stage company with no quarterly revenue and substantial losses, so its valuation depends heavily on future clinical and regulatory progress.

Hedge Funds Weigh In On Lyell Immunopharma

Large investors have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC boosted its holdings in Lyell Immunopharma by 4.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 16,824 shares of the company’s stock worth $158,000 after buying an additional 679 shares during the period. Bank of New York Mellon Corp purchased a new position in Lyell Immunopharma during the 2nd quarter valued at approximately $347,000. Walleye Capital LLC bought a new stake in Lyell Immunopharma in the first quarter worth $445,000. Squarepoint Ops LLC raised its stake in Lyell Immunopharma by 119.4% during the second quarter. Squarepoint Ops LLC now owns 42,322 shares of the company’s stock valued at $595,000 after purchasing an additional 23,028 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in Lyell Immunopharma by 314.2% during the first quarter. Bank of America Corp DE now owns 33,321 shares of the company’s stock valued at $668,000 after purchasing an additional 25,276 shares in the last quarter. Hedge funds and other institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell’s research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.